Form 4: Aclaris Therapeutics Interim CEO Neal Walker Reports Stock Transactions
SEC Form 4 Filing
Interim CEO of Aclaris Therapeutics, Neal Walker, reports acquisition and disposal of common stock related to restricted stock units.
Summary
- On April 1, 2024, Neal Walker, Interim President and CEO of Aclaris Therapeutics, acquired 9,467 shares of common stock upon the vesting of restricted stock units.
- On the same day, Walker disposed of 3,224 shares at $1.26 to cover tax withholding obligations.
- Following these transactions, Walker directly owns 1,285,688 shares of Aclaris Therapeutics common stock and 123,067 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 04/01/2024 | Date of stock acquisition and disposal. |
| 04/03/2024 | Date of signature by Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.